SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

SRT3

178.35

-1%↓

ORNBV.FI

71.3

+0.49%↑

ROVI.ES

53.1

-0.28%↓

OPM.FR

12.9

+0.08%↑

GLPG

28.84

+0.7%↑

Search

Pharming Group NV

Închisă

1.047 2.85

Rezumat

Modificarea prețului

24h

Curent

Minim

1.013

Maxim

1.059

Indicatori cheie

By Trading Economics

Venit

-18M

-15M

Vânzări

-14M

79M

EPS

-0.02

Marjă de profit

-18.61

Angajați

404

Statistici piață

By TradingEconomics

Capitalizare de piață

8.2M

617M

Deschiderea anterioară

-1.8

Închiderea anterioară

1.047

Pharming Group NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 21:42 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug. 2025, 21:21 UTC

Câștiguri
Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug. 2025, 21:30 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 21:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug. 2025, 21:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss $938M >RIG

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug. 2025, 20:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug. 2025, 20:15 UTC

Câștiguri

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug. 2025, 20:13 UTC

Câștiguri

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug. 2025, 20:09 UTC

Câștiguri

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug. 2025, 20:06 UTC

Câștiguri

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparație

Modificare preț

Pharming Group NV Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.